An integrated digital pathology and functional tissue study of risk stratification in penile squamous cell carcinoma

Closing date: 23/11/2026

Clinical Research Training Fellowship: An integrated digital pathology and functional tissue study of risk stratification in penile squamous cell carcinoma 

Lead Supervisors: Professor Rob Bristow
Co-Supervisors: 
Mr Ashwin Sachdeva, Professor Peter Hoskin, Dr Pedro Oliveira, Mr Arie Parham

Applications Deadline: 12:00pm Monday 23rd November 2026
Interviews: Friday 5th February 2027 (in Manchester) 
Start date: September 2027

Project Keywords: Penile cancer, metastatic risk, spatial biology 
Research Opportunity: Clinical Research Training Fellowship leading to the award of PhD

Project Outline

Penile squamous cell carcinoma (PSCC) is a rare malignancy in which surgery is the main treatment modality. However, patients suffer substantial physical, psychological and sexual morbidity. There is a need for reproducible biomarkers that can identify patients at sufficiently low risk of inguinal nodal disease to consider less morbid, penile-preservation management strategies, including loco-regional radiotherapy for cure. 

PSCCs harbour two distinct clinicopathological entities as defined by the WHO 2022 guidelines: HPV-associated (and therefore p16 immunohistochemistry positive) and HPV-independent1 with p16 positivity predicting more favourable outcomes 2,3. However p16-HPV status and the partially subjective clinical pathology features (i.e. lesion grade & depth, lymphovascular and perineural invasions) do not capture tumour microenvironment (TME; immune, stromal cells and hypoxic sub-regions) heterogeneity nor uniformly predict inguinal metastases 4,5,6.  This project will develop a reproducible digital and spatial pathology model for PSCC inguinal nodal metastasis to generate the evidence and framework for future prospective multidisciplinary and biomarker-driven preservation treatments  

 

Central hypothesis 

Quantitative PSCC features of tumour–stroma organisation (tumour budding, pattern of invasion);  immune-cell distribution (Tumour Infiltrating Lymphocytes; TILs), coupled with spatial transcriptomics, provides a signature for low risk of inguinal nodal involvement and excellent radioresponse.  

 

Primary aim 

To develop a clinically calibrated digital pathology-based risk stratification for predicting inguinal nodal metastasis and potential cure with radiotherapy in PSCC. 

 

Additional/Secondary aims 

  1. Define spatial and molecular features associated with pathology-derived low and high-risk nodal states 
  2. Compare risk-state features between matched primary/inguinal lymph-node tumours  
  3. Establish ex vivo models (organoids) of primary for experimental therapeutics  

 

Research questions 

  1. Can quantitative digital and spatial pathology improve prediction of inguinal nodal metastasis? 
  2. Are their pathology-defined low/high risk states for inguinal lymph-node metastasis? 
  3. Can patient-derived tissue primary and metastatic models be propagated in vitro and in vivo to provide for the testing of radiotherapy response.  

 

Applications for this project are now open. Please complete your application on The University of Manchester website.

About Professor Rob Bristow (project Lead Supervisor)

Robert Bristow MD PhD FRCPC, is the Director of the Manchester Cancer Research Centre (MCRC), University Professor of Cancer Studies in the Division of Cancer Sciences (The University of Manchester) and Chief Academic Officer at The Christie NHS Foundation Trust.

He was previously a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto and a Senior Scientist at the Princess Margaret Cancer Centre.

His primary research interests are in tumour hypoxia, DNA damage signalling and DNA repair in tumours, and the genomics of prostate cancer progression and cancer treatment response. He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbour aggressive genetic changes and hypoxic sub-regions.

Find out more

Headshot of Professor Rob Bristow

Key information

Before submitting an application, please ensure you have read the information below about the funding arrangements and eligibility for our Clinical Research Training Fellowships.

We also encourage you to get in contact with the lead supervisor to discuss the project and any particulars.

Further information is available on the Clinical Research Training Fellowships webpage.

Useful Links

Submit your application

Interested in applying for this opportunity? Submit your application on The University of Manchester application portal.

Clinical Research Training Fellowships

Discover our various opportunities for clinicians looking to undertake a period of PhD training in a cancer-relevant field.

Get in Touch

Contact Dr Yasmin Noori Jenaghard, Postgraduate Programme Manager.

Researcher Stories

Read first-hand experiences of from cancer scientists from across Manchester.

Why Manchester?

Find out why postgraduate students choose to study in Manchester.

A Day in the Life of a Clinical PhD Student

Watch our short video to see what it's like to be a Clinical Research Training Fellow in Manchester.